🧬 Endocrinology Update: Stem Cell Diabetes Breakthrough, AI Diagnosis, Food Rx and More
From lab to life-changing treatment — this week’s endocrinology roundup brings you the latest innovations in diabetes management, thyroid diagnostics, and osteoporosis care.
📌 In This Episode:
🧪 Zimislecel stem cell therapy helps 10 out of 12 patients with Type 1 Diabetes become insulin-free.
🦠 New gut procedure targets diabetic duodenopathy to improve outcomes in Type 2 Diabetes.
🌏 Tzield, the first FDA-approved therapy to delay Type 1 Diabetes, now launched in China.
💉 Amgen’s MariTide shows sustained weight loss with monthly dosing for Type 2 Diabetes. 🤖 AI models can now predict Type 1 Diabetes risk up to a year in advance.
🥗 Abbott’s food prescription program reduces A1C levels and boosts healthy eating habits.
💊 Biodexa’s oral therapy trial aims to reduce insulin dependence.
🧬 GOLD-STANDARD trial tests powerful four-drug combo to combat diabetic kidney disease.
🔍 AI tool for thyroid cancer diagnoses with greater than 90 percent accuracy.
🏥 Medimaps’ AI software expands across top U.S. hospitals for osteoporosis.
📘 Free digital guide for osteoporosis patients improves adherence and awareness. Whether you’re a healthcare leader, clinician, or innovator, these updates are shaping the future of endocrinology care.
📢 Stay Ahead in Endocrinology Research!
✅ Like, share, and subscribe for weekly updates on diabetes, thyroid disorders, and bone health.
#Endocrinology #DiabetesResearch #Type1Diabetes #Type2Diabetes #ThyroidCancer #Osteoporosis #StemCellTherapy #HealthTech #AIinHealthcare #ClinicalTrials #HealthcareInnovation #MedicalBreakthroughs